Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study

INTRODUCTION: The most frequently reported neurological adverse event of ChAdOx1 nCoV-19 (AZD1222) vaccine is headache in 57.5%. Several cases of cerebral venous thrombosis (CVT) have developed after vaccination. Headache is the leading symptom of CVT. For the differential diagnosis of headaches att...

Descripción completa

Detalles Bibliográficos
Autores principales: Göbel, Carl H., Heinze, Axel, Karstedt, Sarah, Morscheck, Mascha, Tashiro, Lilian, Cirkel, Anna, Hamid, Qutyaba, Halwani, Rabih, Temsah, Mohamad-Hani, Ziemann, Malte, Görg, Siegfried, Münte, Thomas, Göbel, Hartmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314854/
https://www.ncbi.nlm.nih.gov/pubmed/34313952
http://dx.doi.org/10.1007/s40122-021-00296-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314854/
https://www.ncbi.nlm.nih.gov/pubmed/34313952
http://dx.doi.org/10.1007/s40122-021-00296-3

Ejemplares similares